RBC trims BSX target, still likes the stock

Same movie, slightly lower popcorn budget

RBC isn’t bailing on Boston Scientific — it’s just dialing back the upside a bit. The firm cut its price target to $105 from $115 while keeping an Outperform rating, which tells you this is more a reset of expectations than a full-on cold shoulder.

What that means for your portfolio

Price-target cuts can sting, but the real signal is the rating. If a bank lowers the target and still says Outperform, it’s usually saying: “We still think the stock can work, just not quite as explosively as before.” For investors, that can matter because it can influence sentiment without actually changing the underlying long-term thesis.

Why you should care

Boston Scientific often trades on growth expectations, so even small tweaks in analyst confidence can ripple through the stock. A lower target can cap some of the near-term enthusiasm, but the kept-unchanged rating suggests RBC still sees the company as one of the better names in medtech.

Big picture: this is less of a breakup text and more of a “let’s adjust the budget” note.